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ABSTRACT
Background: The UK Department of Health
recommends annual influenza vaccination for
healthcare workers, but uptake remains low. For staff,
there is uncertainty about the rationale for vaccination
and evidence underpinning the recommendation.
Objectives: To clarify the rationale, and evidence
base, for influenza vaccination of healthcare workers
from the occupational health, employer and patient
safety perspectives.
Design: Systematic appraisal of published systematic
reviews.
Results: The quality of the 11 included reviews was
variable; some included exactly the same trials but
made conflicting recommendations. 3 reviews
assessed vaccine effects in healthcare workers and
found 1 trial reporting a vaccine efficacy (VE) of 88%.
6 reviews assessed vaccine effects in healthy adults,
and VE was consistent with a median of 62% (95% CI
56 to 67). 2 reviews assessed effects on working days
lost in healthcare workers (3 trials), and 3 reported
effects in healthy adults (4 trials). The meta-analyses
presented by the most recent reviews do not reach
standard levels of statistical significance, but may be
misleading as individual trials suggest benefit with
wide variation in size of effect. The 2013 Cochrane
review reported absolute effects close to 0 for
laboratory-confirmed influenza, and hospitalisation for
patients, but excluded data on clinically suspected
influenza and all-cause mortality, which had shown
potentially important effects in previous editions.
A more recent systematic review reports these effects
as a 42% reduction in clinically suspected influenza
(95% CI 27 to 54) and a 29% reduction in all-cause
mortality (95% CI 15 to 41).
Conclusions: The evidence for employer and patient
safety benefits of influenza vaccination is not
straightforward and has been interpreted differently by
different systematic review authors. Future uptake of
influenza vaccination among healthcare workers may
benefit from a fully transparent guideline process by a
panel representing all relevant stakeholders, which
clearly communicates the underlying rationale,
evidence base and judgements made.
BACKGROUND
The UK Department of Health (DH) cur-
rently recommends that all healthcare
workers (HCWs) in direct contact with
patients or clients are vaccinated against
inﬂuenza each year.1 2 Although this policy is
not enforced, an aspirational target of 75%
vaccination coverage has been set for all hos-
pital and community services and has
recently been linked to additional funding
known as ‘winter pressure funds’.3
Despite this target, vaccination coverage
among HCWs remains low, at 50.6% during
the 2015–2016 season and 54.9% during the
2014–2015 season.4 5 A systematic review on
self-reported reasons for non-uptake of inﬂu-
enza vaccine by HCWs identiﬁed two major
factors: a wide range of misconceptions or
lack of knowledge about inﬂuenza infection
and lack of convenient access to vaccine.6 On
the reasons for accepting inﬂuenza vaccine,
Strengths and limitations of this study
▪ This study unpicks the three main perspectives
justifying health workers being vaccinated
against influenza and the evidence of an effect
for each. This includes the occupational perspec-
tive, examining the effect on illness; the
employer perspective, examining working days
lost and the patient safety perspective, examining
the effect on transmission to patients.
▪ The analysis draws on published systematic
reviews, which draw on a similar population of
trials, and summaries the results and the con-
sistency of their conclusions.
▪ We conclude from an occupational health per-
spective, there is consistency in the effect of the
vaccine in preventing illness; for the employer
perspective, some meta-analyses are misleading
and the individual trials all seem to show a
reduction in days lost and for an effect on
patient safety, the results are conflicting and
unclear.
▪ The study does not aim to provide recommenda-
tions but suggests a conceptual framework and
evidence summaries that may help frame a
guideline development process to provide clear
messages to help health workers make informed
decisions.
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self-protection was the most important reason. We were
interested in the degree of misconceptions by health
workers in the literature. We noted that systematic
reviews and related papers often draw on the same body
of evidence, reached different conclusions and won-
dered whether this may perhaps contribute to the
muddle, rather than helping.7–9
In this paper, we sought to unpick the different ratio-
nales for vaccination and summarise the evidence base
for each through a critical appraisal and summary of all
available relevant systematic reviews. To do this, we devel-
oped a conceptual framework (ﬁgure 1). This presents
the two main policy options available to the UK DH and
the rationale and evidence requirements for each:
1. Offer vaccination to all HCWs—This policy takes an
occupational health perspective, which could be justi-
ﬁed by evidence of increased risk of inﬂuenza among
staff. Healthcare workers would require reliable evi-
dence on the efﬁcacy and safety of the vaccine and
could opt in or out of vaccination.
2. Frame vaccination as a ‘professional responsibility’
and target high vaccination coverage—This policy
could be justiﬁed from either an employer perspec-
tive: if vaccination reduced sick leave and service dis-
ruption, or a patient safety perspective: if there were
evidence that vaccination of HCWs reduced inﬂuenza
in vulnerable patients.
The current policy as stated in the 2015–2016
Inﬂuenza Plan and Annual Inﬂuenza Letter refers to
the occupational health and patient safety perspectives:
to protect HCWs themselves from inﬂuenza and to
reduce the risk of passing the virus on to vulnerable
patients.5 10
METHODS
The protocol for this evidence appraisal is included in
online supplementary appendix 1. We aimed to include
all systematic reviews, published in English language
journals, which evaluate the effects of inﬂuenza vaccin-
ation in either healthy adults (over 18 years old) or
HCWs (nurses, doctors, nursing and medical students,
other health professionals including ancillary staff) of all
ages. We sought evidence of effects on laboratory-
conﬁrmed inﬂuenza and clinically suspected inﬂuenza
(the occupational health perspective), working days lost
(the employer perspective) and laboratory-conﬁrmed
inﬂuenza, clinically suspected inﬂuenza, death or hospi-
talisation of patients (the patient safety perspective).
Search methods for identification of systematic reviews
Two authors (MK and AK) independently searched
MEDLINE, Embase, CINAHL, AMED and HMIC for all
systematic reviews from January 1990 to December 2015.
Search terms were ‘inﬂuenza vaccine’, ‘adult’, ‘health-
care worker’, ‘doctor’, ‘nurse’, ‘effectiveness’, ‘efﬁcacy’,
‘absence’, ‘systematic review’ and ‘meta-analysis’ (see
online supplementary appendix 2). Bibliographies of
retrieved articles were also searched to identify
additional reviews.
Data collection and analysis
Two authors (MK and AK) independently reviewed titles
and abstracts for inclusion in the review, applied the
inclusion criteria and extracted data onto a standardised
form. For each included review, we extracted informa-
tion on the review objectives, perspective, search strategy,
inclusion criteria, outcome measures, included studies,
risk of bias of included studies, results and conclusions.
Where possible, we only extracted data for inactivated
parenteral vaccines, as per the current UK inﬂuenza vac-
cination programme. Where this distinction was not
clear, we extracted data for all vaccines. In addition,
where possible, we only extracted data for seasonal inﬂu-
enza vaccination. Where this distinction was not clear,
we extracted data for all vaccine schedules. Two
reviewers (MK and AK) independently checked data
extraction for agreement. A third reviewer (DS) was con-
sulted to resolve disagreements.
Two authors (MK and AK) independently appraised
the methodological quality of each review using the
AMSTAR tool for appraising systematic reviews.11
Disagreements were resolved through discussion and,
where necessary, through appraisal by a third author
(DS). The AMSTAR tool required us to make judge-
ments about how well the systematic review authors
applied 11 methodological techniques to reduce bias
and error in their reviews. While these criteria are likely
to identify reviews with major ﬂaws, they are less effective
at detecting errors in interpretation.
Where possible, outcome data are presented as
vaccine efﬁcacy (VE) expressed as a percentage using
the formula: VE=1−relative risk (RR), with 95% CIs.
Where RR was not presented, data are presented as
reported in the source systematic review. The number
needed to vaccinate (NNV) to prevent one case of inﬂu-
enza in healthy adults and HCWs was calculated using
the formula: NNV=1/absolute risk reduction, with 95%
CIs. To estimate the impact from an economic perspec-
tive, the number of prevented working days lost was cal-
culated per 100 HCWs.
We also extracted the authors’ inferences or
recommendations.
RESULTS
The search identiﬁed 2483 unique citations of which
2371 were excluded after screening the title, and a
further 91 were excluded after screening the abstract.
The full inclusion criteria were applied to 23 full text arti-
cles, of which 11 were included. Of the 12 excluded
papers, 10 were excluded as they were not systematic
reviews, 1 was a previous version of a review already
included and 1 did not include data on HCWs or healthy
adults (ﬁgure 2, see online supplementary appendix 3).
One review was supported by an inﬂuenza vaccine
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manufacturer12 and the rest by public bodies or agencies
(table 1).
Of the 11 included systematic reviews, three evaluated
the effects of inﬂuenza vaccination in HCWs12–14 and six
in healthy adults;14–19 ﬁve evaluated the effects in
patients13 14 20–22 and ﬁve evaluated the effects of vaccin-
ation on days off work12–14 16 19 (table 1, see online sup-
plementary appendices 4 and 5). Two Cochrane reviews
were included; the main analysis includes only the most
recent version of the review, but where necessary we
refer back to the earlier editions.
Occupational health perspective: effect on illness
In healthcare workers
Three reviews directly evaluate VE among HCWs12–14
(table 2; see online supplementary appendix 6).
Methodological quality of reviews: Ng and Lai12 was
the most up-to-date review and was judged to be a
high-quality review against the AMSTAR criteria, with
only minor limitations (table 3). Burls et al13 and
Michiels et al14 have major limitations (table 3).
Included studies: Ng and Lai12 and Burls et al13 included
the same three randomised controlled trials (RCTs) enrol-
ling 967 participants. Michiels et al14 included two trials,
both different to those included by Ng and Lai12 and Burls
et al,13 and describe both as RCTs although one is clearly
non-randomised.23 Neither of these trials is mentioned in
the list of excluded studies presented by Ng and Lai.12
Results: Ng and Lai12 and Burls et al13 report a VE of
88% against laboratory-conﬁrmed inﬂuenza, based on a
single trial among 264 hospital HCWs, although Burls
et al13 presents the result stratiﬁed by inﬂuenza virus
type.25 Ng and Lai12 and Burls et al13 report that the
effects on clinically suspected inﬂuenza were not statistic-
ally signiﬁcant across two trials.26 27 In an additional RCT
among 356 dental students reported by Michiels et al,14 28
Figure 1 Perspectives for benefit of influenza vaccination of health workers, evidence required and policy framing for each.
Figure 2 Flow chart of search
process.
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Table 1 Characteristics of included systematic reviews
Review ID Funding source
Search
period/end
date
Perspective reported
Populations of
interest Included vaccines
Included study
designs
No. of
relevant
studies
Occupational
health Employer
Patient
safety
Burls et al13 European Scientific
Working Group on
Influenza
Until June
2004
Yes (HCWs) Yes Yes HCW; patients
(high risk)
Any All 5
Michiels et al14 National Institute for
Health and Disability
Insurance in
Belgium
January 2006
to March
2011
Yes (HCWs and
healthy adults)
Yes Yes HCW; healthy adults
(16–65 years);
patients (no further
definition)
Trivalent inactivated RCTs and non-RCT 10
Ng and Lai12 None stated Date of
launch to
March 2011
Yes (HCWs) Yes No HCW Any RCTs and
non-RCTs
3
Demicheli
et al19
None stated Date of
launch to
May 2013
Yes (healthy
adults)
Yes No Healthy adults
(16–65 years)
Inactivated
parenteral
RCTs and
quasi-RCTs
20
DiazGranados
et al15
Authors employees
of Sanofi Pasteur
Until October
2011
Yes (healthy
adults)
No No Healthy adults
(non-elderly)
Inactivated parent,
live attenuated
intranasal, adjuvant
or recombinant
RCTs and
quasi-RCTs
20
Ferroni and
Jefferson16
None stated Date of
launch to
March 2011
Yes (healthy
adults)
Yes Yes Patients (no further
definition); healthy
adults
Any SRs and RCTs 6
Osterholm
et al17
Alfred P Sloan
Foundation
January 1967
to February
2011
Yes (healthy
adults)
No No Healthy adults
(18–46 years)
Any RCTs and
observational
studies
7
Villari et al18 Italian Ministry of
Health and the
Emilia Romagna
Regional Health
Agency
January 1966
December
2002
Yes (healthy
adults)
No No Healthy adults
(mainly 16–65 years)
Any RCTs and
quasi-RCTs
26
Ahmed et al22 None stated January 1948
to June 2012
No No Yes Patients in
healthcare facilities
Inactivated or live
attenuated
RCTs, cohort,
case–control
studies
6
Dolan et al23 WHO Global
Influenza
Programme
Not stated No No Yes Patients (at high risk
of respiratory
infection)
Any RCTs and
observational
studies (cross
sectional/cohort)
16
Thomas et al21 None stated Date of
launch to
March 2013
No No Yes Patients (aged
>60 years living in
institutions)
Any RCTs and
non-RCTs
3
HCWs, healthcare workers; RCTs, randomised controlled trials; SRs, systematic reviews.
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Table 2 Vaccination effects in healthcare workers (the occupational health perspective)
Review ID Population
Laboratory-confirmed influenza Clinically suspected influenza SR authors’ conclusions
No. of studies
(participants) Efficacy (95% CI)
No. of studies
(participants)
Efficacy
(95% CI) On efficacy For policy
Ng and Lai12 HCW 1 RCT (359) 88% (59 to 96) 2 RCTs (606) No significant
effect in either
study
‘No definitive conclusion
on the effectiveness of
influenza vaccinations in
HCWs’
‘Further research is necessary to
evaluate whether annual
vaccination is a key measure to
protect HCWs’
Burls et al13 HCW 1 RCT (361) 88% (47 to 97) Inf. A
89% (14 to 99) Inf. B
2 RCTs (606) No significant
effect in either
study
‘Vaccination was highly
effective’
‘Effective implementation should be
a priority’*
Michiels et al14 HCW 1 non-RCT (262) 90% (25 to 99) 1 RCT (346) 53% (NS)
p=0.002
None stated None stated
Demicheli et al19 Healthy
adults
22 RCTs
(51 724)
62% (56 to 67) 16 (25 795) 17% (13 to 22) ‘Influenza vaccines have
a very modest effect in
reducing influenza
symptoms’
‘Results seem to discourage the
usage of vaccination against
influenza in healthy adults as a
routine public health measure.’†
DiazGranados
et al15
Healthy
adults
Not stated 59% (50 to 66) – – ‘Influenza vaccines are
efficacious’
None stated
Osterholm
et al17
Healthy
adults
6 (31 892) 59% (51 to 67) – – ‘Influenza vaccines
provide moderate
protection against
confirmed influenza’
None stated
Villari et al18 Healthy
adults
25 (18 920) 63% (53 to 71) 49 (46 022) 22% (16 to 28) ‘Estimates (of effect) vary
substantially’
‘Further trials…are needed to
provide definitive answers for
policymakers’
Michiels et al14 Healthy
adults
14 (21 616) 44% to 73% (range) 19 (19 046) No significant
effect
‘Inactivated influenza
vaccine shows efficacy in
healthy adults’
None stated
Ferroni and
Jefferson16
Healthy
adults
5 (43 830) 44% to 77% (range) 18 (19 046) 7% to 30%
(range)
‘Inactivated vaccines are
effective at reducing
infection’
None stated
*This conclusion may be influenced by the reported effects on protecting patients and days off work in tables 3 and 4, respectively.13
†This conclusion is influenced by the additional findings of no demonstrable effect on complications such as pneumonia or transmission.19
HCW, healthcare worker; RCTs, randomised controlled trials; SR, systematic review.
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Table 3 AMSTAR assessments of methodological quality
AMSTAR criteria
Burls
et al13
Michiels
et al14*
Ng
and
Lai12
Demicheli
et al19
Diaz
Granados
et al15
Ferroni and
Jefferson16*
Osterholm
et al17
Villari
et al18
Ahmed
et al22
Dolan
2012
Thomas
et al21
1. ‘A priori’ design? No No No Yes No No No No No Yes Yes
2. Duplicate study selection and
extraction?
Yes Yes Yes Yes No No No Yes Yes Yes Yes
3. Comprehensive literature
search?
Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes
4. Did they attempt to find
unpublished studies and grey
literature?
Yes No Yes Yes No No No Yes No No Yes
5. List of studies (included and
excluded) provided?
No No Yes Yes No No Yes Yes No No Yes
6. Characteristics of included
studies provided?
Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes
7. Scientific quality of included
studies assessed and
documented?
No Yes Yes Yes Yes No No Yes Yes Yes Yes
8. Scientific quality of included
studies used appropriately in
formulating conclusions?
No Yes Yes Yes Yes Yes No Yes Yes No Yes
9. Appropriate methods used to
combine the findings of
studies?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
10. Likelihood of publication bias
assessed?
No No No No Yes No No Yes No No Yes
11. Conflict of interest stated? No Yes Yes Yes Yes Yes Yes No Yes Yes Yes
Total risk score* 5 6 9 10 7 5 4 9 7 7 11
*Michiels et al14 and Ferroni and Jefferson16 are mainly overviews of reviews and so the AMSTAR criteria may be poorly applicable.
†Note all questions score 1 point for a ‘yes’ answer.
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VE against clinically suspected inﬂuenza was 53%
(p=0.03; table 2).
Consistency of conclusions: Although they evaluated
exactly the same three trials and present similar summar-
ies, Ng and Lai12 and Burls et al13 made very different
inferences: Burls et al13 recommended health worker vac-
cination ‘as a priority’, whereas Ng and Lai12 stated that
‘no deﬁnitive conclusion’ could be made (table 2). The
strong recommendation by Burls et al13 may be inﬂu-
enced by their additional ﬁndings related to protecting
patients and reducing days off work described below.
In healthy adults
In addition, six reviews report VE in healthy adults,
which may reasonably be extrapolated to HCWs12 13 16–18
(table 2, see online supplementary appendix 7).
Methodological quality of reviews: Of the most recent
reviews, Demicheli et al19 was a high-quality review with
only minor limitations, whereas DiazGranados et al,15
Osterholm et al,17 Michiels et al14 and Ferroni and
Jefferson16 had some or major limitations (table 3).
Included studies: Demicheli et al19 included 20 trials of
inactivated parenteral vaccines. The other reviews included
between 6 and 26 studies, inﬂuenced by different inclusion
criteria and search dates. Michiels et al14 only included
studies of trivalent inactivated vaccines, Osterholm et al17
only included studies in people aged 18–46 years and
Ferroni and Jefferson16 and Michiels et al14 summarise the
results of the previous version of the Demicheli Cochrane
review,19 29 plus a few additional trials.
Results: Demicheli et al,19 DiazGranados et al,15
Osterholm et al17 and Villari et al18 report very similar VE
against laboratory-conﬁrmed inﬂuenza despite differ-
ences in the number of included trials (62%, 59%, 59%
and 63%, respectively). Of these only Demicheli et al19
and Villari et al18 report VE against clinically suspected
inﬂuenza, which is much lower (17% and 22%, respect-
ively). The remaining two reviews rely largely on the
results of Jefferson et al29 but only report the range of
effects across trials.
Consistency of conclusions: All six reviews conclude that
the vaccine is effective at preventing laboratory-
conﬁrmed inﬂuenza. However, Demicheli et al19 states
that “the results of this review provide no evidence for
the utilisation of vaccination against inﬂuenza in healthy
adults as a routine public health measure”, perhaps
basing this on their judgement that this efﬁcacy was too
low or on their additional ﬁndings that vaccination did
not reduce complications of inﬂuenza. The oldest
review18 called for more trials, and the remaining four
reviews did not make any policy recommendations.
Employer perspective: effect on working days lost
In healthcare workers
Two reviews described above12 13 include the same three
trials and report the impact of vaccinating HCW on
working days lost.
Methodological quality: see above.
Results: Ng and Lai12 reports a meta-analysis of two of
these trials, which does not reach standard levels of stat-
istical signiﬁcance (mean difference (MD) −0.08 days,
95% CI −0.19 to 0.02, I2=0%, two trials, 540 partici-
pants) and states that the third trial could not be
included in the meta-analysis due to the way the data
were presented. However, Burls et al13 reports that the
third trial found a statistically signiﬁcant reduction in
working days lost of 0.4 (p=0.02) (table 4).
In healthy adults
One Cochrane review reports effects on working days
lost in healthy adults,19 and two other systematic
reviews14 16 simply present the results from an earlier
version of Demicheli et al19 (ref. 28) (table 4).
Methodological quality: see above.
Results: The 2010 version of the Cochrane review29
reported statistically signiﬁcant effects on working days
lost, but the 2014 version19 did not, even though there
were no additional trials.
In the study of Jefferson et al,29 the authors combined
studies where the vaccine was a good match with the cir-
culating virus (MD −0.21 working days lost, 95% CI
−0.36 to −0.05; 4 trials, 4263 participants) and a poor
match (MD 0.09, 95% CI 0.00 to 0.18, one trial, 1130
participants) and present an overall mean reduction of
0.13 working days lost.29 In the updated version,19 the
authors removed one study conducted during the 1960s
pandemic, which had a large effect on working days lost,
and present an overall mean reduction of 0.04 working
days lost. This result does not reach standard levels of
statistical signiﬁcance when using a random effects
model (95% CI −0.14 to 0.06) but becomes statistically
signiﬁcant when a ﬁxed effects model is used (95% CI
−0.06 to −0.01). This difference occurs due to the large
variation in the size of the effect in individual trials, and
consideration of the trials individually is probably more
informative than the meta-analysis: of the four studies
where the vaccine was a good match with the circulating
virus, two reported large effects (MD −0.44 and −0.74,
respectively) and two reported more modest effects (MD
−0.08 and −0.04, respectively). All four results reached
standard levels of statistical signiﬁcance.
Patient safety perspective: effects on patients and clients
Six reviews report the impact of vaccinating HCWs on
their patients or clients13 14 16 20–22 (table 5, see online
supplementary appendix 8).
Methodological quality of reviews: One of the two most
recent reviews21 was of high methodological quality and
had only minor limitations (table 3). The remaining
reviews all have some major limitations.
Included studies: Thomas et al21 evaluated the effects of
vaccinating HCW on people aged over 60 years living in
residential care settings or hospitals and included four
cluster-RCTs (7558 participants) and one cohort study
(12 742 participants). Ahmed et al22 and Dolan et al23
evaluate the same four cluster-RCTs plus some additional
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observational studies. Burls et al13 only includes two of
the cluster-RCTs included in Thomas et al,21 and Michiels
et al14 and Ferroni and Jefferson16 summarise the ﬁnd-
ings of an earlier version of Thomas et al21 30
Results: Thomas et al21 reports absolute effect estimates
close to zero for laboratory-conﬁrmed inﬂuenza (risk
difference (RD) 0.00, 95% CI −0.03 to 0.03; two trials,
752 participants), hospitalisation (RD 0.00, 95% CI
−0.02 to 0.02; 1 trial, 3400 participants) and death due
to lower respiratory tract infection (RD −0.02, 95% CI
−0.06 to 0.02; 2 trials, 4459 participants). Thomas et al21
state that they chose not to present results on clinically
suspected inﬂuenza and all-cause mortality because
‘these are not the effects the vaccines were produced to
address’ and give further reasons why they believe this is
important in appendices. They did, however, include
these outcomes in their previous version,30 and three of
the other reviews simply refer to the results for these
outcomes reported in the Cochrane review (Dolan
2012).14 16 Dolan et al23 also presents the results of three
observational studies, which report statistically signiﬁcant
effects on clinically suspected inﬂuenza. Ahmed et al22
analyses the same four RCTs but includes the two add-
itional outcomes with statistically signiﬁcant and quanti-
tatively important effects: a reduction in clinically
suspected inﬂuenza of 42% (95% CI 27 to 54, 3 trials,
7031 participants) and a reduction in all-cause mortality
of 29% (95% CI 15 to 41, 4 trials, 8468 participants).
Conclusions: Thomas et al21 and the earlier version of
this Cochrane review concluded that they ‘did not iden-
tify a beneﬁt of healthcare worker vaccination’. Dolan
et al20 concludes a ‘likely protective effect for patients’
(based mainly on the outcomes of the earlier edition of
the Cochrane review) and that the evidence base is ‘suf-
ﬁcient to sustain current policy’. Ahmed et al22 con-
cludes vaccinating healthcare professionals ‘can
enhance patient safety’.
DISCUSSION
Occupational health perspective
The efﬁcacy of inﬂuenza vaccination against laboratory-
conﬁrmed inﬂuenza is remarkably consistent across
reviews, at around 60% in healthy adults. It seems reason-
able to extrapolate this effect to HCWs (who are them-
selves often ‘healthy adults’), and indeed the single trial
directly assessing efﬁcacy in HCWs is consistent with this.
Using the median efﬁcacy of 62%, and the median risk of
inﬂuenza in the control groups of 4%, vaccination would
prevent ∼2.5 episodes of inﬂuenza per 100 HCW vacci-
nated (a NNV to prevent one case of inﬂuenza of around
40 (95% CI 36 to 52)). The decision about whether to
offer vaccination to HCWs (ﬁgure 1; vaccine policy one)
would then depend on a value judgement as to whether
this effect was considered worthwhile and further evi-
dence that the vaccine was safe, acceptable to HCWs and
affordable to the health service.
Table 4 Vaccination effects on the health system (the employer perspective)
Review ID Population
Days off work Review authors’ conclusions
No. of studies
(participants)
Mean difference
(days) On efficacy For policy
Ng and Lai12 HCW 2 (540) –0.08 (95% CI –0.19 to
0.02) (third study not
included in
meta-analysis)
‘No definitive
conclusion on the
effectiveness of
influenza vaccinations
in HCWs’
‘Further research is
necessary to evaluate
whether annual vaccination
is a key measure to protect
HCWs’
Burls et al13 HCW 3 (967) Statistically significant
difference in only one
of the three studies
(MD 0.4 days, p=0.02)
‘Vaccination was
highly effective’
‘Effective implementation
should be a priority’*
Demicheli
et al19
Healthy
adults
4 (3726) Good match—three
studies (2596), MD=
−0.09 (−0.19 to 0.02)
Matching absent/
unknown—one study
(1130), MD=0.09 (0.00
to 0.18)
‘A modest effect on
time off work’
‘No evidence for the usage
of vaccination against
influenza in healthy adults
as a routine public health
measure’†
Michiels et al14 Healthy
adults
Not stated Not stated (refers to
Jefferson 2010)
None stated None stated
Ferroni and
Jefferson16
Healthy
adults
1 meta-analysis
including 5
studies (5393)
Good match—0.21
Matching absent/
unknown—0.09 (refers
to Jefferson 2010)
‘May be marginally
more effective than
placebo’
None stated
*This conclusion may be influenced by the reported effects on vaccine efficacy and protecting patients in tables 2 and 3, respectively.13
†This conclusion is influenced by the additional findings of no demonstrable effect on complications such as pneumonia or transmission.19
HCW, healthcare worker; MD, mean difference.
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Table 5 Vaccination effects in patients or clients of HCW (the patient safety perspective)
Review ID
Patient
group
Laboratory-confirmed influenza Clinically suspected influenza
Other statistically
significant effects
Review authors’ conclusions
No. of studies
(participants)
Efficacy
(95% CI)
No. of studies
(participants) Efficacy On efficacy For policy
Burls
et al13
Those at
risk. No
further
definition
Not reported Not reported Not reported Not reported Deaths from all-cause
mortality, OR=0.56,
p=0.0013
‘Vaccination was
highly effective’*
‘Effective
implementation
should be a priority’†
Michiels
et al14
No further
definition
Refers to 2010
version of
Thomas et al21
No statistically
significant effect
Refers to 2010
version of
Thomas et al21
No statistically
significant effect
Deaths from all-cause
mortality
Effectiveness=34%
(95% CI 21 to 45)
‘There is little
evidence that
immunisation is
effective in
protecting patients’
‘Should not be
mandatory at present’
Ferroni and
Jefferson16
People aged
at least
60 years in
long-term
care facilities
Two RCTs
Refers to 2011
version of
Thomas et al21
No statistically
significant effects
Refers to 2011
version of
Thomas et al21
86% where some
patients
vaccinated to no
significant effect
where patients
unvaccinated
Deaths from all-cause
mortality, RR=0.66
(95% CI 0.55 to 0.79)
(unadjusted)
‘Influenza
vaccination of
healthcare workers
and the older people
in their care may be
more effective at
reducing
influenza-like illness
in older people living
in institutions,
although vaccination
of healthcare
workers alone may
be no more effective’
None stated
Ahmed
et al22
Patients in
healthcare
facilities. No
further
definition
Two RCTs
(752)
One
observational
study
RCTs—No
statistically
significant effects
Observational
study (≥35% vs
<35% vaccinated
HCWs)—adjusted
OR=0.07 (0.01 to
0.98)
Three RCTs
(7031)
One
observational
study
RCTs—42%
(95% CI 27 to 54)
Observational
study—no
significant effect
Deaths from all-cause
mortality, RR=0.71
(95% CI 0.59 to 0.85)
‘Healthcare
professional
influenza vaccination
can enhance patient
safety’
None stated
Continued
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Employer perspective
The most recent reviews in HCWs and all healthy adults
present meta-analyses, which do not reach standard levels
of statistical signiﬁcance. However, these may be mislead-
ing due to either failure to include all the trials or the
wide variation in effect size seen in the individual trials.
While even the conservative estimate of four working
days saved per 100 people vaccinated (taken from the
latest Cochrane review) would inevitably reduce some dis-
ruption to the health workforce, estimates of how much
this would save or cost the National Health Service are
needed and are beyond the scope of this review.
Patient safety perspective
It is not unreasonable to postulate that vaccinating
HCWs with an effective vaccine will reduce transmission
of inﬂuenza to patients. However, the data available
from trials, the data presented in reviews and the con-
clusions reached by authors are somewhat confusing.
The best supportive evidence seems to come from ana-
lyses of VE against clinically suspected inﬂuenza and all-
cause mortality, which were present in Ahmed et al22
and the 2010 version of the Cochrane review, although
discounted in the conclusions reached and then
removed from the latest version of the Cochrane review
despite showing important effects. Although we accept
that these outcomes have limitations, we are unsure if
excluding them was the right decision, especially if trials
are adequately blinded, and the data on laboratory-
conﬁrmed inﬂuenza are insufﬁcient to exclude effects.
In a fully transparent process, these data would be
clearly presented alongside an evaluation of the cer-
tainty of the evidence (assessed by GRADE) for consid-
eration by the reader or the guideline panel, rather than
the authors simply deciding to exclude it.
The direct evidence (from systematic reviews of
RCTs), for employer or patient safety effects which
would lead to policy option two (framing high vaccin-
ation coverage as a professional responsibility), is
nuanced and has suffered from being the subject of
multiple systematic review teams, making different infer-
ences from the same data. Occasionally, these authors
have stepped beyond the brief of systematic reviews to
make recommendations based on author judgements,31
which have only served to muddy the waters and add to
the confusion surrounding vaccination. Evidence of
effects from systematic reviews is only one component of
evidence-informed policymaking, and judgements about
the relative importance of different outcomes, or the
clinical importance of estimated effects, are best made
by a panel who adequately represent all important stake-
holder groups, including patients, carers and HCWs,
such as Joint Committee on Vaccination and
Immunisation ( JCVI).
Strengths and limitations of this paper
This paper did not aim to undertake an appraisal of the
quality of evidence for each of the policy-relevant
Ta
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outcomes. This would have comprised doing our own
systematic review, and clearly there are already enough
of these. Rather we have concentrated on appraising the
existing systematic reviews and unpicking the reasons for
the inconsistencies between their conclusions. We also
did not aim to make judgements or recommendations
of our own, as we are not the right people to do so, and
this would simply add to the confusion around vaccin-
ation. We would, however, encourage dialogue between
the Cochrane review teams and the relevant policy-
makers to ensure that future editions include all the out-
comes relevant to decision-making and a transparent
appraisal of the quality of evidence using the GRADE
approach.
We chose to include only systematic reviews in English,
as these are most likely to have inﬂuenced HCWs and
policymakers in the UK, although further reviews in
other languages may exist and be important to policies
elsewhere. We chose to restrict our analysis to inactivated
parenteral vaccines where possible as this is what is
recommended in the UK.
CONCLUSIONS
HCWs are increasingly used to seeing, and demanding
to see, the evidence base for the healthcare interven-
tions they are asked to provide or make themselves
subject to. Consequently, inﬂuenza vaccination uptake
may beneﬁt from a fully transparent guideline process,
which makes explicit the underlying rationale, evidence
base, values, preferences and judgements, which inform
the current or future policy. This process would draw on
all available direct evidence from systematic reviews and
the most up-to-date research but may also use indirect
evidence such as health system data on working days lost
due to inﬂuenza.
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Contributors SG initiated the development of this paper. All authors had
substantial contributions to conception and design of the paper and
interpretation of the data. MK and AK collected and analysed the data.
PG proposed the appraisal structure, and DS developed the conceptual
framework. MK drafted the manuscript, and all authors contributed to
developing the manuscript. All authors have given final approval of the
version to be published and agree to be accountable for all aspects of the
work in ensuring that questions related to the accuracy or integrity of any part
of the work are appropriately investigated and resolved. MK is responsible for
the overall content as guarantor. MK affirms that the manuscript is an honest,
accurate and transparent account of the study being reported; that no
important aspects of the study have been omitted and that any discrepancies
from the study as planned have been explained. All authors, external and
internal, had full access to all of the data (including statistical reports and
tables) in the study and can take responsibility for the integrity of the data
and the accuracy of the data analysis.
Funding PG and DS are partly supported by the Effective Health Care
Research Consortium. This Consortium is funded by UK aid from the
UK Government for the benefit of developing countries (grant: 5242). The
views expressed in this publication do not necessarily reflect UK government
policy. Public Health England paid the open access fees for publication.
Competing interests MK, AK and SG are employed by Public Health England;
PG has an honorary contract with Public Health England and PG and DS are
employed by a grant that supports Cochrane.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Department of Health, Public Health England, NHS England. The
national flu immunisation programme 2014/15 (updated 28 April
2014; cited 3 December 2014). https://www.gov.uk/government/
uploads/system/uploads/attachment_data/file/316007/
FluImmunisationLetter2014_accessible.pdf
2. Public Health England, NHS England. Seasonal flu vaccine uptake
in healthcare workers: 1 September 2015 to 31 January 2016
(published 18 February 2016). https://www.gov.uk/government/
statistics/seasonal-flu-vaccine-uptake-in-healthcare-workers-1-
september-2015-to-31-january-2016 (accessed 25 May 2016).
3. British Medical Association. BMA criticises staff flu-jab funding link
(updated 9 October 2014; cited 18 May 2016). http://www.bma.org.
uk/news-views-analysis/news/2014/october/bma-criticises-staff-flu-
jab-funding-link
4. Public Health England. Seasonal influenza vaccine uptake amongst
frontline healthcare workers (HCWs) in England Winter season 2015
to 2016 (updated May 2016; cited 26 May 2016). https://www.gov.
uk/government/uploads/system/uploads/attachment_data/file/
526041/Seasonal_influenza_vaccine_uptake_HCWs_2015_16_
Annual_Report.pdf
5. Public Health England, NHS England. Flu plan: winter 2015 to 2016.
(updated March 2015; cited 17 September 2015). https://www.gov.
uk/government/uploads/system/uploads/attachment_data/file/
418038/Flu_Plan_Winter_2015_to_2016.pdf
6. Hollmeyer HG, Hayden F, Poland G, et al. Influenza vaccination of
health care workers in hospitals—a review of studies on attitudes
and predictors. Vaccine 2009;27:3935–44.
7. McCartney M. Show us the evidence for the flu jab. Pulse Today.
19 October 2011 (cited 7 August 2014). http://www.pulsetoday.co.uk/
show-us-the-evidence-for-the-flu-jab/12911759.article
8. McCartney M. What use is mass flu vaccination? BMJ 2014;349:g6182.
9. Doshi P. Influenza: marketing vaccine by marketing disease. BMJ
2013;346:f3037.
10. Department of Health, Public Health England, NHS England. The
national flu immunisation programme 2015 to 2016: supporting letter
(updated 27 March 2015, cited 17 September 2015). https://www.
gov.uk/government/uploads/system/uploads/attachment_data/file/
418428/Annual_flu_letter_24_03_15__FINALv3_para9.pdf
11. Shea B, Bouter L, Peterson J, et al. External validation of a
measurement tool to assess systematic Reviews (AMSTAR). PLoS
One 2007;2:e1350.
12. Ng AN, Lai CK. Effectiveness of seasonal influenza vaccination
in healthcare workers: a systematic review. J Hosp Infect
2011;79:279–86.
13. Burls A, Jordan R, Barton P, et al. Vaccinating healthcare workers
against influenza to protect the vulnerable—is it a good use of
healthcare resources? A systematic review of the evidence and an
economic evaluation. Vaccine 2006;24:4212–21.
14. Michiels B, Govaerts F, Remmen R, et al. A systematic review
of the evidence on the effectiveness and risks of inactivated
influenza vaccines in different target groups. Vaccine
2011;29:9159–70.
15. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine
efficacy and its determinants in children and non-elderly adults:
a systematic review with meta-analyses of controlled trials. Vaccine
2012;31:49–57.
16. Ferroni E, Jefferson T. Influenza. Clin Evid (Online) 2011:pii 0911.
17. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and
effectiveness of influenza vaccines: a systematic review and meta-
analysis. Lancet Infect Dis 2012;12:36–44.
18. Villari P, Manzoli L, Boccia A. Methodological quality of studies and
patient age as major sources of variation in efficacy estimates of
influenza vaccination in healthy adults: a meta-analysis. Vaccine
2004;22:3475–86.
19. Demicheli V, Jefferson T, Al-Ansary L, et al. Vaccines for preventing
influenza in healthy adults. Cochrane Database Syst Rev 2014;(3):
CD001269.
Kliner M, et al. BMJ Open 2016;6:e012149. doi:10.1136/bmjopen-2016-012149 11
Open Access
group.bmj.com on September 16, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
20. Dolan GP, Harris RC, Clarkson M, et al. Vaccination of healthcare
workers to protect patients at increased risk of acute respiratory
disease: summary of a systematic review. Influenza Other Respir
Viruses 2013;7(Suppl 2):93–6.
21. Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for
healthcare workers who care for people aged 60 or older living in
long-term care institutions. Cochrane Database Syst Rev 2013;(7):
CD005187.
22. Ahmed F, Lindley MC, Allred N, et al. Effect of influenza vaccination of
healthcare personnel on morbidity and mortality among patients:
systematic review and grading of evidence.Clin Infect Dis 2014;58:50–7.
23. Dolan GP, Harris RC, Clarkson M, et al. Vaccination of health care
workers to protect patients at increased risk for acute respiratory
disease. Emerg Infect Dis 2012;18:1225–34.
24. Michiels B, Philips H, Coenen S, et al. The effect of giving influenza
vaccination to general practitioners: a controlled trial. BMC Med
2006;4:17.
25. Wilde J, McMillan J, Serwint J, et al. Effectiveness of influenza
vaccine in health care professionals: a randomized trial. JAMA
1999;281:908–13.
26. Weingarten S, Staniloff H, Ault M, et al. Do hospital employees
benefit from the influenza vaccine? A placebo-controlled clinical trial.
J Gen Intern Med 1988;3:32–7.
27. Saxén H, Virtanen M. Randomized, placebo-controlled double blind
study on the efficacy of influenza immunization on absenteeism of
health care workers. Pediatr Infect Dis J 1999;18:779–83.
28. Hui L, Rashwan H, bin Jaafar M, et al. Effectiveness of influenza
vaccine in preventing influenza-like illness among Faculty of
Dentistry staff and students in University Kebangsaan Malaysia.
Healthc Infect 2008;13:4–9.
29. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing
influenza in healthy adults. Cochrane Database Sys Rev 2010;(7):
CD001269.
30. Thomas R, Jefferson T, Lasserson T. Influenza vaccination for
healthcare workers who work with the elderly. Cochrane Database
Syst Rev 2010;(2):CD005187.
31. Cochrane Handbook. Chapter 12: Interpreting results and drawing
conclusions (cited 8 October 2014). http://handbook.cochrane.org/
v5.0.0/chapter_12/12_interpreting_results_and_drawing_
conclusions.htm
12 Kliner M, et al. BMJ Open 2016;6:e012149. doi:10.1136/bmjopen-2016-012149
Open Access
group.bmj.com on September 16, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
and policy options
in the UK: appraisal of systematic reviews 
Influenza vaccination for healthcare workers
Garner
Merav Kliner, Alex Keenan, David Sinclair, Sam Ghebrehewet and Paul
doi: 10.1136/bmjopen-2016-012149
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/9/e012149
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/9/e012149
This article cites 18 articles, 3 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1735)Public health
 (458)Infectious diseases
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on September 16, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
